Pharsight

Drugs that contain Liraglutide Recombinant

1. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
SAXENDA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(1 year, 9 months ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 9 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 9 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 9 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(1 year, 3 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 1 month ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(3 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(7 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 3 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 5 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 5 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 9 months from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(1 year, 9 months from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(1 year, 11 months from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(2 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(2 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(8 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SAXENDA family patents

Family Patents

2. Victoza patents expiration

VICTOZA's oppositions filed in EPO
VICTOZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 7 months ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

USRE41956

(Pediatric)

NOVO NORDISK INC Dose setting limiter
Jul, 2021

(2 years ago)

US8846618 NOVO NORDISK INC Stable formulation of modified GLP-1
Jun, 2022

(1 year, 9 months ago)

US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1
Dec, 2022

(1 year, 3 months ago)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 1 month ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(3 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(7 months from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(1 year, 9 months from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button
Mar, 2033

(8 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-176) Apr 22, 2019
New Patient Population(NPP) Jun 17, 2022
New Indication(I-750) Aug 25, 2020
Pediatric Exclusivity(PED) Dec 17, 2022
M(M-115) Apr 06, 2015
New Chemical Entity Exclusivity(NCE) Jan 25, 2015

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

VICTOZA family patents

Family Patents